DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

0090-9556/03/3107-846-853$20.00
DMD 31:846-853, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watanabe, T.
Right arrow Articles by Hammock, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watanabe, T.
Right arrow Articles by Hammock, B. D.

IN VITRO METABOLISM OF THE MAMMALIAN SOLUBLE EPOXIDE HYDROLASE INHIBITOR, 1-CYCLOHEXYL-3-DODECYL-UREA

Takaho Watanabe, Christophe Morisseau, John W. Newman, and Bruce D. Hammock

Department of Entomology and Cancer Research Center, University of California, Davis, California

The metabolism of the soluble epoxide hydrolase (sEH) inhibitor, 1-cyclohexyl-3-dodecyl-urea (CDU), was studied in rat and human hepatic microsomes. The microsomal metabolism of CDU enhanced sEH inhibition potency of the reaction mixture and resulted in the formation of several metabolites. During the course of this study, a sensitive and specific high-performance liquid chromatography with tandem mass spectrometry analytical method was developed to investigate simultaneously the production of these metabolites. In both rat and human hepatic microsomes, CDU was ultimately transformed into the corresponding {omega}-carboxylate; however, the rodent tissue appeared to perform this transformation more rapidly. After a 60-min incubation in rat hepatic microsomes, the percentage of residual CDU, the {omega}-carboxylate, and the intermediary {omega}-hydroxyl were about 20%, 20%, and 50%, respectively. Carbon monooxide inhibited the metabolism of CDU by rat hepatic microsomes, suggesting that the initial step is catalyzed by cytochrome P450. Further metabolism was enhanced by the addition of NAD, suggesting that dehydrogenases are associated with intermediate metabolic steps. Regardless, the ultimate product of microsomal metabolism, 12-(3-cyclohexyl-ureido)-dodecanoic acid, is also an excellent sEH inhibitor with several hundred-fold higher solubility, supporting the hypothesis that CDU has prodrug characteristics. These findings will facilitate the rational design and optimization of sEH inhibitors with better physical properties and improved metabolic stability.

Address correspondence to: Bruce D. Hammock, Department of Entomology & Cancer Research Center, University of California, Davis, CA 95616. E-mail: bdhammock{at}ucdavis.edu




This article has been cited by other articles:


Home page
 HypertensionHome page
J. D. Imig, X. Zhao, C. Z. Zaharis, J. J. Olearczyk, D. M. Pollock, J. W. Newman, I.-H. Kim, T. Watanabe, and B. D. Hammock
An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension
Hypertension, October 1, 2005; 46(4): 975 - 981.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
X. Zhao, T. Yamamoto, J. W. Newman, I.-H. Kim, T. Watanabe, B. D. Hammock, J. Stewart, J. S. Pollock, D. M. Pollock, and J. D. Imig
Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage
J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1244 - 1253.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.